The Neuroblastoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Neuroblastoma: An Overview
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.
Stages of neuroblastoma determine the extent of the spread of the tumor in the patients, and the disease is staged on the basis of results of physical exams, imaging tests, and biopsies of the main tumor and other tissues. The staging of neuroblastoma is based on two classification systems: International Neuroblastoma Staging System (INSS) and International Neuroblastoma Risk Group Staging System (INRGSS).
Neuroblastoma is most common in very young children, but it is rare in children over the age of 10 years. Approximately 1% to 2% of patients with neuroblastoma inherit an increased risk of developing neuroblastoma from their parents.
As per the study by Heck et al., titled “The epidemiology of neuroblastoma: a review,” in one North American review of 3,059 cases, 40% of patients were diagnosed in infancy, 89% by age 5 and 98% by age 10. In most countries, boys are diagnosed at rates equivalent to or slightly higher than girls.
Neuroblastoma Market Key Facts
The total Incident population of Neuroblastoma in the seven major markets was observed to be more than 1,500+ in 2017.
DelveInsight’s estimate suggests a higher incidence of neuroblastoma in the United States, as compared to EU-5 countries and Japan, with a 620+ Incident population in 2017.
Among the European countries, France has the highest Incident population of Neuroblastoma with 150+ cases, followed by the United Kingdom which has an Incident population of 140+ in 2017. On the other hand, Spain has the lowest Incident population of 90+ cases in 2017.
Japan witnessed more than 250+ incident cases of neuroblastoma in 2017.
As per the study conducted by Shohet et al., titled “Epidemiology, pathogenesis, and pathology of neuroblastoma,” the median age at diagnosis is 17.3 months, and 40% of patients are diagnosed before one year of age.
As per Delveinsight, the Neuroblastoma market size is expected to show positive growth, mainly attributed to increased incidence and also due to the expected launch of emerging therapies during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Neuroblastoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Neuroblastoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The epidemiology section covers insights into the historical and current Neuroblastoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Neuroblastoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroblastoma market or expected to get launched in the market during the study period. The analysis covers Neuroblastoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Neuroblastoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/neuroblastoma-market
Neuroblastoma Therapeutics Analysis
Companies across the globe are thoroughly working towards the development of new treatment therapies for Neuroblastoma. While some of the companies have recently shifted their focus towards this indication, which is expected to create a significant influence on the market size during the forecast period.
Some of the key companies in the Neuroblastoma Market include:
United Therapeutics Corp
And many others
Neuroblastoma therapies covered in the report include:
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/neuroblastoma-market
Table of Content
1. Key Insights
2. Executive Summary
3. Neuroblastoma Competitive Intelligence Analysis
4. Neuroblastoma Market Overview at a Glance
5. Neuroblastoma Disease Background and Overview
6. Neuroblastoma Patient Journey
7. Neuroblastoma Epidemiology and Patient Population
8. Neuroblastoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Neuroblastoma Unmet Needs
10. Key Endpoints of Neuroblastoma Treatment
11. Neuroblastoma Marketed Products
12. Neuroblastoma Emerging Therapies
13. Neuroblastoma Seven Major Market Analysis
14. Attribute Analysis
15. Neuroblastoma Market Outlook (7 major markets)
16. Neuroblastoma Access and Reimbursement Overview
17. KOL Views on the Neuroblastoma Market.
18. Neuroblastoma Market Drivers
19. Neuroblastoma Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/neuroblastoma-market
Trending Healthcare Reports By DelveInsight
DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States